The Razor's Edge
2-Year Price History
Recent Price
(12/3/2008)
$16.62
52-Week Price
$14.26 - $24.24
Market Capitalization
$112.1 Billion
Most Recent Dividend
$1.16
About Pfizer, Inc.
Pfizer, Incorporated is considered to operate in the Healthcare
sector. They specifically operate in the Drug Manufacturers/Major
business segment contained within the Drugs industry.
A research-based, global pharmaceutical company which discovers, develops, manufactures and markets prescription medicines for humans and animals.
Ockham's Rating
Pfizer, Incorporated has been downgraded as of the time of this report. The reason for the downgrade is neither the price change (4.85% since our last report) nor the earnings expectations for Pfizer, Incorporated (PFE) have been significant enough to cause a ratings change. We have observed a decrease in the attractiveness of the Healthcare sector, of which Pfizer, Incorporated is a part. The valuation of this sector has decreased in relation to the other sectors, and we have adjusted all stocks within the Healthcare sector to account for this change in attractiveness.
PFE Stock Evaluation
As the Recommendation Summary above points out, there has not been a significant change to PFE’s price or fundamentals. However, we never look at a security and ignore it’s relation to the overall market and its individual sector. In the case of PFE, the Healthcare sector is seeing a sharp decline in its relative standing to the other sectors studied by Ockham. Given this decline in attractiveness, it has become necessary to downgrade PFE as well as many of its peers. Be sure to read our Sector and Peer Analysis to see the other securities that this general down turn may be affecting in the Healthcare sector.
PFE Revenue
As a value investing shop, we are interested in seeing how PFE's revenues measure up against past performances. One easily understandable way of doing that is to compare Price to Sales per share levels over a given time frame. Assuming it is available, Ockham prefers to look at ten years of history (for this stock there are 10 years of history available) and we weigh recent years more heavily. This allows us to find weighted average historical high and low Price to Sales ratios, which give us a better idea of the stock's current underlying value. Using this method, we have established a high range for Price to Sales of 4.95x and the low end of the range at 3.37x.
With respect to these historically rational metrics, notice that the current Price to Sales per share ratio for PFE of 2.27x is well below its normal historic Price to Sales levels. At a price of $16.43, PFE is 46% below where we would expect to see it. Clearly, this stock looks undervalued compared to historical levels, at least on a Price to Sales basis. This will positively affect our analysis because it is rare to find a stock this far below historical norms, and we would expect some price appreciation to bring this metric back towards a more normal range.
PFE Cash Earnings
As a value investment framework, Ockham Research is similar to a private equity firm in terms of our valuation methods. We are always on the lookout for value in the form of sales and cash numbers. In the case of PFE, Ockham views their current Cash Earnings as significantly below its historical average multiple of Cash Earnings. Looking at the last 10 years we can get a good understanding of what investors have grown to expect from PFE. For example, PFE's Cash Earnings ratio per share has fluctuated between 11.74 and 17.09 over this historical timeframe. This range is based upon a proprietary weighted methodology at Ockham, but can clearly show an investor where PFE is with respect to prior business periods.
So with PFE's current price (latest close of $16.43) and most recent level of Cash Earnings reported, we see significant opportunity from a value perspective. At its current price level, PFE is 66% below its average level of Price to Cash Earnings on a historical basis. This means that investors were willing to pay for a much higher stock price than currently for the same level of Cash in the past, on a relative basis. There are a couple of important things to remember, however. First, value doesn't exist in a vacuum. So if the market doesn't recognize this value, even a great disparity in Price to Cash Earnings cannot force an immediate stock price reaction. Second, patience is key when looking at securities that have reached these levels of Price to Cash Earnings versus their historical norms. So be patient with PFE.
PFE Dividends
A strong dividend payment history is looked upon as a favorable characteristic on a company’s future and potentially can receive a positive Ockham rating. That being said, we don't require dividend payments for company's whose management has elected to forgo them entirely.
When reviewing dividend yields for PFE, we compare the historic high and low levels over the past, which is similar to our evaluation of Sales and Cash Earnings per share. Paying a dividend is not necessary for any company, but changes in dividend often can lend clues as to the health of the business. A rising dividend is a strong sign for an established company, as it reflects management's confidence in the company. PFE’s estimated annual dividend is $1.28 resulting in a current dividend yield of 7.79%. The highest dividend yield from PFE over recent history was 8.98% while the lowest dividend yield was 0.73%. PFE’s current dividend yield is therefore significantly higher than its median dividend yield historically. In fact, the current yield is 60.45% above the median which weighs very positively on our analysis of PFE.
Community Discussion